O Albania Division of Neurosciences, Mario Negri Institute for Pharmacological Study IRCCS, Milan, Italy; bMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; c Department of Clinical Neurosciences, Faculty of Brain Sciences, University Trypanosoma Accession College London Institute of Neurology, London, UKacPOSTECH, Pohang, Republic of Korea; Division of Urology, Seoul St. MMP-13 Accession Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Division of Laboratory Medicine, Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul; dDepartment of Mechanical Engineering, POSTECH, Pohang, Republic of KoreabIntroduction: Analysing extracellular vesicles (EVs) is an eye-catching signifies in prostate cancer diagnosis. Having said that, existing procedures of EVs isolation have low efficiency, purity and extended method time, which induce low diagnostic capacity. To approach the issues, we adapt a two-phase program to diagnose prostate cancer by isolating EVs from patients’ urine. Using the twophase method, prostate hyperplasia (BPH) patients and prostate cancer (PCA) individuals have been diagnosed, and theIntroduction: Extracellular vesicles (EVs) represent an ideal supply of biomarkers resulting from their part in cellular communication and their ability to carry protein aggregates. By far the most investigated EVs are exosomes, active entities secreted from cells and in a position to cross the blood brain barrier. Several neurodegeneration-involved molecules might undergo intercellular spreading via exosome release. In Alzheimer’s disease (AD), just before clinical indicators seem, a number of proteins implicated in exo- and endocytic pathways are altered. In thisJOURNAL OF EXTRACELLULAR VESICLESscenario, the identification of a correlation in between variations in proteins carried by EVs as well as the progression of AD is definitely the major aim of our project. Techniques: We performed exosome isolation and characterization from H4-SW glioma cells (a cell model featuring mutated -amyloid overexpression), also as in mouse(triple-transgenic mouse model for familial AD) and human-plasma samples (Mild Cognitive Impairment (MCI) and AD subjects). In every case, a differential centrifugation protocol was applied and exosomes were then characterized employing Nanoparticle Tracking Evaluation with all the NanoSight. We then explored exosome content, specifically Amyloid Precursor Protein (APP) and its proteolytic fragments, Microtubule Associated Protein Tau (tau), Progranulin (PGRN protein), Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) and synuclein (-syn), using Western blot and ELISA. L1CAM and CD63 have been evaluated to define the neural-derived exosomes quantity in human samples. Each of the samples had been collected just after ethical committee approval respecting Helsinki’s declaration. Informed consents have been offered by all the subjects. Results: Our preliminary benefits show that APP, PGRN and sTREM2 are carried by H4- and human plasmaderived EVs. H4-SW cell-culture medium and 3Tg mouse plasma had a reduce inside the EVs quantity release (110e8 EVs/mL) in comparison to control (710e8 EVs/mL). This decrease was not located in human plasma samples. Summary/Conclusion: EVs purified from H4-glioma cellular AD model, 3xTg mouse-, MCI- and ADplasma samples carry proteins relevant for neurodegenerative illnesses (NDs). EVs release is reduced in cellular and animal AD-models. Funding: Horizon 2020 Marie Sklodowska-Curie Innovative Coaching Networks Blood Biomarker-ba.